Ferroptosis-centered Drug Response Information
General Information of the Drug (ID: ferrodrug0237)
| Name |
Isoorientin
|
||||
|---|---|---|---|---|---|
| Synonyms |
Isoorientin; Homoorientin; 4261-42-1; iso-orientin; Lespecapitioside; Luteolin-6-C-glucoside; Luteolin 6-C-glucoside; CHEBI:17965; 2-(3,4-Dihydroxyphenyl)-6-beta-D-glucopyranosyl-5,7-dihydroxy-4H-1-benzopyran-4-one; UNII-A37342TIX1; LUTONARETIN; Luteolin-6-C-beta-D-glucoside; A37342TIX1; 6C-hexosyl luteolin; 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-6-((2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)-4H-chromen-4-one; 6-Glc-luteolin; (1S)-1,5-anhydro-1-[2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-4-oxo-4H-chromen-6-yl]-D-glucitol; 2-[3,4-bis(oxidanyl)phenyl]-6-[(2S,3R,4R,5S,6R)-6-(hydroxymethyl)-3,4,5-tris(oxidanyl)oxan-2-yl]-5,7-bis(oxidanyl)chromen-4-one; 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-6-[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]chromen-4-one; Homoori-entin; 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-6-beta-D-glucopyranosyl-5,7-dihydroxy-; (1S)-1,5-anhydro-1-(2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-4-oxo-4H-chromen-6-yl)-D-glucitol; MFCD00017433; Homoorientin; Isoorientin; 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-6-((2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl)chromen-4-one; SCHEMBL23761; MLS002473101; CHEMBL239559; Isoorientin, analytical standard; Luteolin 6-C-bet.-D-glucoside; Isoorientin, >=98% (HPLC); DTXSID50962609; 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-6-.beta.-D-glucopyranosyl-5,7-dihydroxy-; luteolin-6-C-B-D-glucopyranoside; ODBRNZZJSYPIDI-VJXVFPJBSA-N; HMS2225D20; HY-N0767; Isoorientin, >=98.0% (HPLC); BDBM50487756; s9248; AKOS015896766; CCG-208392; CS-7515; NCGC00163566-01; AC-34983; AS-56302; SMR001397203; I1087; C01821; Q-100474; Q3155592; Isoorientin, primary pharmaceutical reference standard; 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-6-[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydropyran-2-yl]chromen-4-one; 61383-35-5; H9R
Click to Show/Hide
|
||||
| Structure |
 |
||||
| Formula |
C21H20O11
|
||||
| IUPAC Name |
2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-6-[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]chromen-4-one
|
||||
| Canonical SMILES |
C1=CC(=C(C=C1C2=CC(=O)C3=C(O2)C=C(C(=C3O)C4C(C(C(C(O4)CO)O)O)O)O)O)O
|
||||
| InChI |
InChI=1S/C21H20O11/c22-6-14-17(27)19(29)20(30)21(32-14)16-11(26)5-13-15(18(16)28)10(25)4-12(31-13)7-1-2-8(23)9(24)3-7/h1-5,14,17,19-24,26-30H,6H2/t14-,17-,19+,20-,21+/m1/s1
|
||||
| InChIKey |
ODBRNZZJSYPIDI-VJXVFPJBSA-N
|
||||
| PubChem CID | |||||
Full List of Ferroptosis Target Related to This Drug
Nuclear factor erythroid 2-related factor 2 (NFE2L2)
| In total 1 item(s) under this Target | |||||
| Experiment 1 Reporting the Ferroptosis-centered Drug Act on This Target | [1] | ||||
| Target for Ferroptosis | Marker/Suppressor | ||||
| Responsed Disease | Lung cancer | ICD-11: 2C25 | |||
| Responsed Regulator | NAD-dependent protein deacylase sirtuin-6 (SIRT6) | Suppressor | |||
| Pathway Response | Fatty acid metabolism | hsa01212 | |||
| Ferroptosis | hsa04216 | ||||
| Cell Process | Cell ferroptosis | ||||
| Cell proliferation | |||||
| In Vitro Model | A-549 cells | Lung adenocarcinoma | Homo sapiens | CVCL_0023 | |
| In Vivo Model |
The A549/DDP tumor cells were subcutaneously injected (2 x 106 cells/mL) into BALB/c-nu mice under aseptic conditions. 6 days later, the average diameter of the tumor reaches 0.5 cm, and the mice were randomly divided into the 1 mg/kg DDP group and the 1 mg/kg DDP + 25mg/kg IO group. Six mice from each group were intraperitoneally administered medications every 2 days for a total of 10 doses each.
Click to Show/Hide
|
||||
| Response regulation | Isoorientin (IO) can promote ferroptosis and reverse drug resistance in lung cancer through the SIRT6/Nrf2/GPX4 signaling pathway, thus offering a theoretical basis for its potential clinical application. | ||||